The Current Ratio as of November 2024 (TTM) for Foghorn Therapeutics Inc. (FHTX) is 4.77

According to Foghorn Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.77. This represents a change of 2.43% compared to the average of 4.66 of the last 4 quarters.

Foghorn Therapeutics Inc. (FHTX) Historical Current Ratio (quarterly & annually)

How has FHTX Current Ratio performed in the past?

The mean historical Current Ratio of Foghorn Therapeutics Inc. over the last ten years is 6.28. The current 4.77 Current Ratio has changed 7.50% with respect to the historical average. Over the past ten years (40 quarters), FHTX's Current Ratio was at its highest in in the March 2021 quarter at 10.12. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Foghorn Therapeutics Inc. (FHTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Foghorn Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Foghorn Therapeutics Inc. (FHTX) Average Current Ratio

How has FHTX Current Ratio performed in the past?

The current Current Ratio of Foghorn Therapeutics Inc. (FHTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Foghorn Therapeutics Inc. (FHTX) Current Ratio vs. Peers

How is FHTX’s Current Ratio compared to its peers?

Foghorn Therapeutics Inc.’s Current Ratio is less than C4 Therapeutics, Inc. (6.31), less than Cyteir Therapeutics, Inc. (21.89), less than Prelude Therapeutics Incorporated (7.04), less than Rezolute, Inc. (13.79), less than Shattuck Labs, Inc. (7.96), less than Monte Rosa Therapeutics, Inc. (6.03), less than Kymera Therapeutics, Inc. (8.55), less than Nurix Therapeutics, Inc. (5.28), less than Molecular Partners AG (14.33), less than MediciNova, Inc. (16.66), greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Champions Oncology, Inc. (0.69), less than PMV Pharmaceuticals, Inc. (13.98), less than Stoke Therapeutics, Inc. (5.09), less than Century Therapeutics, Inc. (10.39), less than Edgewise Therapeutics, Inc. (26.35), less than Mineralys Therapeutics, Inc. (8.55), less than Cullinan Oncology, Inc. (24.46),

Build a custom stock screener for Foghorn Therapeutics Inc. (FHTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Foghorn Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Foghorn Therapeutics Inc. (FHTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Foghorn Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.